AstraZeneca lifts 2024 outlook
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
AstraZeneca now expects 2024 revenue and core earnings per share to grow by a high-teens percentage, from a previous forecast ...
The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...
British drug maker AstraZeneca Plc (AZN.L, AZN) announced Tuesday a $3.5 billion capital investment in the United States, aiming to ...
Astrazeneca has raised its guidance for the full year despite issues surrounding its presence in China according to today's ...
AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not ...
AstraZeneca (AZN.L, AZN) reported third quarter profit to owners of the Parent of $1.43 billion compared to $1.37 billion, last year.
AstraZeneca’s results were helped by resilient demand for its cancer and rare diseases medicines, after third-quarter ...
Wuxi International Life-Science Innovation Campus signed a strategic cooperation agreement with the Hong Kong Centre for ...
AstraZeneca is scheduled to report results for the third quarter on Tuesday. Here is what to know. CORE EARNINGS PER SHARE: One of the Anglo-Swedish pharmaceutical major's preferred metrics, core ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback